1 domain / 2 areas / 1 specialization
Apeiron Investment Group
Also known as: Apeiron
Family office and investment group with repeated financing participation in psychedelic drug-development companies, including atai Life Sciences.
Investor Snapshot
Venture CapitalClassification
Family Office
Geography
Global
Coverage
Global
Last Verified
Apr 17, 2026
Investment Stage Focus
Investment Focus Areas
Investor Notes
Apeiron is Christian Angermayer's family office and is publicly listed as a lead/co-lead investor in atai financing rounds.
Verification
Verified
Psychedelic Focus
Explicit Psychedelic Focus
Engagement Status
Active
Recorded Investments
Jul 1, 2025
Private placement financing (co-led) - $50m financing
atai $50m private placement financingNov 23, 2020
Series C financing (co-led) - $125m financing round
Date uses press release date.
ATAI closes $125m Series C financing roundSource Evidence
atai Series C Financing (Co-led by Apeiron)
https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-closing-125-million-series-c/
atai Private Placement (Co-led by Apeiron)
https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-50-million-private-placement
Apeiron Investment Group Website
https://apeiron-investments.com/
Quick Facts
- Website
- Visit